Join Growin Stock Community!
Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-chart

RXRX EPS

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for RXRX's EPS in Q1'26 shows a loss of -0.22 USD, marking a modest deterioration from the previous quarter's -0.17 USD in Q4'25 but remaining within the company's ongoing pattern of negative earnings. This figure reflects continued operational challenges, with the EPS loss narrowing compared to earlier periods like Q4'24's -0.57 USD. Over the period from Q2'23 to Q1'26, RXRX's EPS has exhibited a volatile yet gradually improving trend, starting at -0.38 USD and fluctuating between -0.57 USD and -0.17 USD, with notable declines in Q3'23 (-0.43 USD) and Q4'24 before a sharper recovery in Q4'25. Year-over-year EPS growth has been inconsistent, ranging from -40% in Q4'23 to a strong +70.2% in Q4'25 and +56% in Q1'26, indicating accelerating progress toward reduced losses driven by potential revenue gains or cost efficiencies in the biotech sector. Overall, the bar chart highlights persistent unprofitability, while the overlaid line chart for YoY growth suggests positive momentum in recent quarters.